MedPath

Impact of Insomnia Treatment on Brain Responses During Resting-state and Cognitive Tasks

Not Applicable
Recruiting
Conditions
Chronic Insomnia
Interventions
Behavioral: Cognitive-Behavioural therapy for insomnia (CBT-I)
Registration Number
NCT04024787
Lead Sponsor
Concordia University, Montreal
Brief Summary

Individuals with chronic insomnia have persistent difficulty falling and staying asleep, as well as complaints of altered daytime functioning that may be associated with cognitive impairments. The neural processes underlying these daytime complaints may involve abnormal activation of brain regions and neural networks involved in working memory, memory encoding and emotions. The goal of this study is to assess whether a psychological treatment for insomnia will reverse these abnormalities in brain responses to cognitive tasks and at rest. A secondary objective of the study is to characterize impairments in attentional processing and assess if the impairments can be reversed by the psychological treatment. We hypothesized that the psychological treatment for insomnia will lead to a normalization of the brain responses to working memory, declarative memory encoding, insomnia-related stimuli, and the functional connectivity within the default-mode and limbic networks.

Detailed Description

Study hypothesis

Brain responses associated with working memory task and declarative memory encoding will be decreased in chronic insomnia compared to good sleepers and, among individuals with chronic insomnia, cognitive-behavioral therapy for insomnia will lead to larger recovery in these brain responses, compared to a 3-month wait period.

Brain responses to emotional stimulation, especially to insomnia-related stimuli, will be increased in chronic insomnia compared to good sleepers, and, among individuals with chronic insomnia, cognitive-behavioral therapy for insomnia will lead to larger reduction in these brain responses, compared to a 3-month wait period.

Connectivity in the default-mode and limbic networks during resting-state will be increased in chronic insomnia compared to good sleepers, and, among individuals with chronic insomnia, cognitive-behavioral therapy for insomnia will lead to larger reduction in this connectivity, compared to a 3-month wait period.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
120
Inclusion Criteria

80 participants with chronic primary insomnia (40 per group) 40 good sleepers

Exclusion Criteria
  1. Older than 65 y.o. or younger than 25 y.o.
  2. Contraindication to the MRI scanning
  3. Current neurological disorder
  4. Past history of brain lesion
  5. Major surgery (i.e., requiring general anesthesia) in the past 3 months
  6. Untreated thyroid disorder
  7. Chronic pain syndrome self-reported as interfering with sleep
  8. Recent and severe infection in the past 3 months
  9. Active cancer, or remitted cancer with cancer treatment within the last 2 years
  10. Stroke
  11. Myocardial infarct
  12. Arterial bypass or angioplasty
  13. Pacemaker
  14. Heart failure causing limitation of ordinary physical activity
  15. Renal insufficiency
  16. Sleep apnea with an apnea-hypopnea index > 5/h
  17. Restless legs syndrome with symptoms 3 days or more per week
  18. Periodic limb movements during sleep with index > 15/h
  19. REM-sleep behavior disorder
  20. Narcolepsy and other central disorders of hypersomnolence
  21. Sleepwalking more than once/month
  22. Having worked on night shifts or rotating shifts for more than 2 weeks in the last 3 months or expecting to do so during the study period
  23. Severe mental disorders: bipolar disorder (Type I), schizophrenia, anxiety disorders, major depressive disorder, current substance use disorder, current post-traumatic stress disorder
  24. Current suicidality
  25. Frequent alcohol consumption (>10 glasses/week) or use of cannabis (more than once a week) or illicit drugs (more than once a month)
  26. Smoking cigarettes more than 10 cigarettes/day
  27. Pregnant or breastfeeding women
  28. Current psychotherapy or past cognitive-behavioural therapy for insomnia
  29. Current use of medication for depression or anxiety
  30. Unable to stop hypnosedative medications for at least 2 weeks prior to the first assessment
  31. For good sleepers: insomnia symptoms more than 3 times/ week.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Immediate interventionCognitive-Behavioural therapy for insomnia (CBT-I)-
Primary Outcome Measures
NameTimeMethod
Functional magnetic resonance imaging (fMRI) to examine brain responses to working memory with increasing task difficulty3 months

Functional magnetic resonance imaging (fMRI) will be used to look at changes in brain activations to working memory in individuals with chronic insomnia compared to good sleepers, as well as the modifications in these brain activations after cognitive-behavioral therapy for insomnia.

Functional magnetic resonance imaging (fMRI) to examine brain responses to insomnia-related stimuli3 months

Functional magnetic resonance imaging (fMRI) will be used to look at changes in brain activations to insomnia-related pictures in individuals with chronic insomnia compared to good sleepers, as well as the modifications in these brain activations after cognitive-behavioral therapy for insomnia.

Functional magnetic resonance imaging (fMRI) to examine brain responses to declarative memory encoding3 months

Functional magnetic resonance imaging (fMRI) will be used to look at changes in brain activations to declarative memory encoding in individuals with chronic insomnia compared to good sleepers, as well as the modifications in these brain activations after cognitive-behavioral therapy for insomnia.

Functional magnetic resonance imaging (fMRI) to examine functional connectivity within the default-mode and limbic networks at rest3 months

Functional magnetic resonance imaging (fMRI) will be used to look at changes in resting state functional connectivity in individuals with chronic insomnia compared to good sleepers, as well as the modifications in this functional connectivity after cognitive-behavioral therapy for insomnia, with a focus on the default-mode and limbic networks.

Secondary Outcome Measures
NameTimeMethod
PSG total sleep time3 months

Total sleep time from overnight polysomnography

Dim light melatonin onset (DLMO)3 months

Objective measure of central circadian timing (dim light melatonin onset; DLMO) will be obtained from hourly evening saliva samples

Temporal experience of pleasure scale (adapted version)3 months and 1 year

Self-reported measure of anticipatory and consummatory facets of pleasure. Total score ranges from 18 to 52 (higher score reflects greater pleasure).

Munich Chronotype Questionnaire (MCTQ)3 months and 1 year

Questionnaire on self-reported sleep habits, assessing individual chronotype (e.g., early type, normal type late type).

Trier Inventory for Chronic Stress - short form3 months and 1 year
PSG wake-after-sleep-onset (WASO)3 months

Duration of wake-after-sleep-onset from overnight polysomnography

Insomnia Severity Index (ISI)3 months and 1 year

Self-reported insomnia severity

Pittsburgh Sleep Quality Index (PSQI)3 months and 1 year

Self-reported sleep quality

Sleep latency3 months

Sleep latency from 14-day actigraphy

Wake-after-sleep-onset (WASO)3 months

Duration of wake-after-sleep-onset from 14-day actigraphy

PSG sleep efficiency3 months

Sleep efficiency from overnight polysomnography

Spindle density3 months

Number of sleep spindles per minute of stage N2-N3 sleep from overnight polysomnography

Heart rate variability3 months

Heart rate variability will be measured using the electrocardiogram leads during the overnight assessments

Blood pressure3 months

Blood pressure is assessed using an oscillometer measurement of systolic and diastolic blood pressure in the morning following the overnight assessments

Circulating interleukin-63 months

Markers will be quantified using blood sample during the overnight assessments

Circulating tumor necrosis factor-alpha3 months

Markers will be quantified using blood sample during the overnight assessments

Daytime Insomnia Symptom Response Scale (DISRS)3 months and 1 year

Self-report measures assessing sleep-related rumination

Sleep efficiency3 months

Sleep efficiency from 14-day actigraphy

PSG sleep latency3 months

Sleep latency from overnight polysomnography

Circulating C-reactive protein3 months

Markers will be quantified using blood sample during the overnight assessments

Circulating neurotrophic factor BDNF3 months

Markers will be quantified using blood sample during the overnight assessments

State-Trait Inventory for Cognitive and Somatic Anxiety (STICSA)3 months and 1 year
Sahlgrenska Academy Self-reported Cognitive Impairment Questionnaire (SASCI-Q, adapted version)3 months and 1 year

Questionnaire assessing self-reported (subjective) memory complaints. Total score ranges from 29 to 203 (higher score reflects more self-reported cognitive complaints).

Work and Social Adjustment Scale (WSAS)3 months and 1 year

Self-reported measure assessing perceived functional impairment associated with insomnia. Total score ranges from 0 to 40 (lower score reflects less impairment).

Attention3 months

Attention will be assessed using computerized divided attention and multitasking tasks assessed in the evening and morning of the overnight assessments

GABA3 months

GABA concentration from Magnetic Resonance Spectroscopy (in the anterior cingulate cortex)

Positive and Negative Affect Schedule3 months and 1 year
Total sleep time3 months

Total sleep time from 14-day actigraphy

Diagnosis of insomnia disorder3 months and 1 year

A trained interviewer evaluates the presence of an insomnia disorder using the SCID-V

Sleep stage durations (N1, N2, N3, REM)3 months

Durations of each sleep stage from overnight polysomnography

Arousal index3 months

Number of EEG arousals per hour from overnight polysomnography

Beck Depression Inventory (BDI)3 months and 1 year
Beliefs and Attitudes about Sleep (DBAS)3 months and 1 year
Cortical thickness3 months

Brain morphometric measure from MRI

Cortisol3 months

Cortisol will be assessed using salivary samples collected at bedtime, awakening and 45 minutes after awakening

Gray matter volume (GMV)3 months

Brain morphometric measure from MRI

White matter integrity (fractional anisotropy, mean diffusivity)3 months

Brain measure from MRI

The Implicit Positive and Negative Affect Test (IPANAT)3 months and 1 year
Fatigue symptom inventory3 months and 1 year
Subjective happiness scale3 months and 1 year

Self-reported measure of global subjective happiness. Total score ranges from 4 to 28 (higher score reflects greater happiness).

Trial Locations

Locations (1)

Perform Center, Concordia University

🇨🇦

Montréal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath